mTOR inhibitors are established treatment options for cancers of the breast, kidney and pancreas.2–4 However, the efficacy recorded with these agents is generally modest, making it imperative to find additional strategies to further enhance the limited single-agent clinical efficacy. Here, MTOR is linked to cancer.